BioArctic AB
STO:BIOA B

Watchlist Manager
BioArctic AB Logo
BioArctic AB
STO:BIOA B
Watchlist
Price: 202 SEK -5.08% Market Closed
Market Cap: 17.8B SEK
Have any thoughts about
BioArctic AB?
Write Note

P/E
Price to Earnings

-76.7
Current
-55.7
Median
22.1
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-76.7
=
Market Cap
17.9B SEK
/
Net Income
-232.9m SEK
All Countries
Close
Market Cap P/E
SE
BioArctic AB
STO:BIOA B
17.9B SEK -76.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -181 249.3
US
Abbvie Inc
NYSE:ABBV
318.1B USD 62.6
US
Amgen Inc
NASDAQ:AMGN
142.2B USD 33.6
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 929.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD -219.3
US
Epizyme Inc
F:EPE
94.1B EUR -471.4
AU
CSL Ltd
ASX:CSL
135.7B AUD 32
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 16.9
US
Seagen Inc
F:SGT
39.3B EUR -54.6
NL
argenx SE
XBRU:ARGX
36.2B EUR -135.8
Earnings Growth P/E to Growth
SE
BioArctic AB
STO:BIOA B
Average P/E: 214.8
Negative Multiple: -76.7
192%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 249.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.6
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.6
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
929.1
77%
12
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -219.3
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.4 N/A N/A
AU
CSL Ltd
ASX:CSL
32
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.8 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-100.4
2-Years Forward
P/E
78.2
3-Years Forward
P/E
26.6

See Also

Discover More